| [June 25, 2014] |
 |
Day Three of the 2014 BIO International Convention to Feature Former Secretary of State Hillary Rodham Clinton, Innovative Approaches for Transforming the Current Model for Developing New Treatments, and Approaches for Unlocking R&D Value
SAN DIEGO --(Business Wire)--
The 2014
BIO International Convention, the world's largest biotechnology
event, entered its third day today at the San Diego Convention Center.
It will run through Thursday, June 26. Hosted by the Biotechnology
Industry Organization, this year's event is expected to attract more
than 3,000 biotechnology companies and more than 15,000 attendees from
48 states and 65 countries.
Upcoming Convention Highlights Include:
-
Keynote Luncheon: Hillary
Rodham Clinton, Former Secretary of State, Wednesday, June
25
Media Coverage: The event is open to the
press. All members of the media who attend the event must check in -
and be provided credentials at Media Registration. Names and IDs will
be checked. Seating for print media is NOT GUARANTEED. Once designated
seating is full, media will be directed to an overflow room.
Media
entrance: Media may enter at the D/E entrances
Live
Truck Pre-Set: 8:00 AM PDT
Broadcast Pre-Set: 9:30
AM PDT *Note the change in broadcast pre-set
time
Still Photography Pre-Set: 11:00 AM PDT
IMPORTANT
NOTE: Those bringing still cameras will be escorted to set
location. All photographs will be captured within the first five
minutes of the Keynote.
-
Super Session: EY
2014 Biotechnology Industry Report, Wednesday, June 25
Ernst
& Young's 2014 biotechnology industry report explores approaches that
allow companies to "unlock value" by conducting R&D in ways that are
both more capital-efficient and better aligned with the need to
demonstrate value. The report highlights three such approaches:
precision medicine, adaptive trials and pre-commercial collaborations.
-
Super Session: AMP-lifying
Innovation: NIH, Patient Organizations & Leading Biopharma Firms
Mobilize to Tackle Tough Diseases, Wednesday, June 25
The
Accelerating Medicines Partnerships (AMP) is a new venture among the
NIH, several non-profit organizations and 10 biopharmaceutical
companies focused on transforming the current model for developing new
treatments. The Session will highlight the goals and implementation
plans for the new AMP program as well as explore the evolution of
large-scale public private partnerships in an evolving innovation
ecosystem.
-
Press Conference: BIO
Ventures for Global Health to Announce New African Drug
Development and Capacity Building Initiatives, Wednesday, June 25
BIO
Ventures for Global Health (BVGH), a nonprofit organization dedicated
to building partnerships to help solve global health issues will
announce two new, indigenous African drug development partnership
programs at the 2014 BIO International, Convention, June 25 at 3:15pm
in room 27A at the San Diego Convention Center. Speakers will also
include Dr. Solomon Nwaka, Director and Head, of the African Network
for Drugs and Diagnostics Innovation (ANDI) and Deputy
Executive Secretary, Mr. Akinbode Samuel Agbaoye of the
National Universities Commission (NUC) of Nigeria along with Mr.
Christopher J. Maiyaki, Chief of Staff to the Executive Secretary and
CEO of NUC. The speakers will describe research partnership
opportunities and objectives of Africa's leading research institutions
through BVGH partnering activities and programs.
-
Integrating
Personalized Medicine into the Healthcare Equation,
Wednesday, June 25
The science driving personalized
medicine continues to push innovation in medicine towards better
patient (diagnosis, treatments, and cures). However, the regulatory,
reimbursement, healthcare practice and research environments are not
currently conducive to experiencing the full potential of personalized
medicine. This panel will explore these challenges, and suggest policy
solutions that are critical to the success of personalized medicine.
-
Patient-Focused
Drug Development: Is the Promise Materializing?, Wednesday,
June 25
This session will discuss provisions in the 2012
FDA Safety and Innovation Act intended to facilitate patient
involvement in drug development. These include an initiative to
incorporate patient perspectives on disease severity and medical need
into the review process; a FDASIA section to foster participation of
patient representatives in appropriate FDA meetings with medical
product sponsors and investigators and a new, more systematic and
transparent framework to outline and ommunicate FDA benefit-risk
approval decisions to the public.
-
Successful
Industry-Disease Foundation Partnerships: A National Survey and
Leadership Perspective, Wednesday, June 25
Disease
foundations are playing an increasingly important role in advancing
research and helping to bring new treatments to market. Their unique
expertise in specific disease areas can be invaluable to developing
and disseminating new research tools, technologies and clinical
protocols. In addition, these organizations have a keen understanding
of patient needs, and access to clinical thought leaders and patients,
which can enhance and accelerate the clinical development of new
treatments. Industry and foundation executives share what they view as
the key opportunities and challenges for industry-foundation
collaborations.
-
Regulatory
Transformation: As Alzheimer's Disease, Science, Research and Advocacy
Move Toward Earlier Detection and Intervention, How Will Researchers
Adapt to this Evolution?, Wednesday, June 25
If
realized, disease-modifying interventions targeted toward Alzheimer's
disease - treatments which actually slow or halt disease progression -
would be a tremendous breakthrough for patients, family members and
researchers. Research into disease-modifying interventions is
increasingly targeted toward earlier stage patients. Although early
intervention may offer the most promise for patients, this earlier
focus creates challenges for researchers who have traditionally been
asked to provide co-primary outcome measures which demonstrate both
the cognitive as well as functional impacts of therapy. In order to
identify the appropriate clinical trial endpoints - those which
demonstrate clinical meaningfulness of treatment effects in the
earlier stages of disease - a robust dialogue between researchers,
regulators, patients, and caregivers must take place. In this session,
a panel of notable researchers, informed advocates, and regulatory
experts will present an overview of the current paradigm, discuss the
anticipated challenges as research focuses earlier, and debate future
requirements.
-
Are
Vaccines Still Blockbuster Products?, Wednesday, June 25
This
session will look forward at the possible growth opportunities in the
global vaccines market. The last ten years saw the launch of several
multi-billion dollar vaccines such as the conjugated pneumonia and HPV
vaccines. Were these vaccines just rare events in the market or are
there other products that represent growth in global vaccines? Are new
pediatric vaccines the only true blockbusters or does the future point
to specialized vaccines against nosocomial infections, chronic
diseases and cancer? Panelists will discuss the prospects for both
global and niche vaccines and whether the projected growth of the
vaccine market is possible.
-
Will
Innovation Have a Place in the Evolving U.S. Healthcare Market?,
Wednesday, June 25
The term "value" is swiftly pushing the
U.S. marketplace through system-wide changes, particularly since the
passage of health reform. Most health care stakeholders are growing
increasingly concerned that value is a euphemism for cost, rather than
a healthy balance of cost, quality and patient outcomes, and fear it
may eventually discourage future innovations. Launching new products
in an environment where unit cost reigns over total cost of care and
outcomes will be challenging. In other parts of the world, assessing a
product's value is well-established and is part of the decision-making
process. Learn how biopharmaceuticals, payers and providers will
incorporate the drive for value in their U.S. organizations moving
forward.
Day Two Session Highlights Included:
-
The
BIO/Battelle State Initiatives Report 2014: The Impact of the
Biosciences in State Economic Vitality
This year's
BIO/Battelle State Initiatives Report describes the size, scope and
performance of the bioscience industry sector at the national, state
and metro level and reports on trends in state bioscience industry
development efforts. A panel of state Governors examined in detail a
series of key performance metrics and discussed state policies and
programs designed to accelerate the growth of the biosciences. The
discussion panel provided an analysis on where the industry stands
today and how states can continue fostering a bioscience economy in
challenging economic times.
-
Integrate
and Collaborate to Drive Advancements in Oncology Treatments
BioCentury
Editor Susan Schaeffer led a Super Session in which panelists
discussed the pressing need for companies to increase collaboration
with each other and with industry stakeholders, including patient
advocacy groups and academic medical centers, to speed the development
and delivery of new medicines.
Follow the 2014 Convention @BIOConvention,
and join the conversation @IAmBIOtech.
Media registration is open from 7:00am - 6:30pm at the San Diego
Convention Center. The Convention program features more than 160
sessions in 8 breakout sessions and 9 specialty forums. The majority of
attendees, 70 percent, are c-level executives. They split evenly from
large companies of 500 or more employees and small companies of 50
employees or less.
The BIO International Convention is the largest global event for the
biotechnology industry and attracts the biggest names in biotech, offers
key networking and partnering opportunities, and provides insights and
inspiration on major trends affecting the industry. The Convention will
highlight the latest trends and the newest opportunities for executives,
investors, scientists, policy leaders, and media from around the world.
Speakers at the sessions will share breakthroughs in medicine,
diagnostics, the environment, energy production, business operations,
financing, partnerships, policy issues and food and agriculture. Visit http://convention.bio.org/program/
for the most up-to-date program and speaker information.
The Convention also features the BIO Business Forum, which has grown
over the past thirteen years to become the industry's largest partnering
event. This year's Convention is set to break all previous partnering
records, with over 28,000 meetings expected to take place. Powered by
BIO's One-on-One Partnering™ System, the BIO Business Forum™ fosters the
opportunity for companies to initiate business contacts in a friendly
environment and schedule private meetings prior to the Convention.
Upcoming BIO Events
BIO
Latin America Conference
September 9-11, 2014
Rio de
Janeiro, Brazil
Livestock
Biotech Summit
September 16-18, 2014
Sioux Falls, SD
About BIO
BIO is the world's largest trade association representing biotechnology
companies, academic institutions, state biotechnology centers and
related organizations across the United States and in more than 30 other
nations. BIO members are involved in the research and development of
innovative healthcare, agricultural, industrial and environmental
biotechnology products. BIO also produces the BIO
International Convention, the world's largest gathering of the
biotechnology industry, along with industry-leading investor and
partnering meetings held around the world. BIOtechNOW
is BIO's blog chronicling "innovations transforming our world" and the
BIO Newsletter is the organization's bi-weekly email newsletter. Subscribe
to the BIO Newsletter.
For more information:
Visit http://www.bio.org
Follow
us on Twitter
@IAmBiotech
Join us on LinkedIn/MyBio
Become
a fan at facebook.com/IAmBiotech
[ Back To TMCnet.com's Homepage ]
|
